Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR Revive Therapeutics Ltd (31R.MU) Follow Add holdings 0.0180 0.0000 (0.00%) At close: April 25 at 8:04:35 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 31R.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 31R.MU View More All News Press Releases SEC Filings Revive Therapeutics Announces Proposed Shares for Debt Transaction Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program Revive Therapeutics Announces Results of Annual Shareholder Meeting Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections